Omalizumab (Xolair) + Placebo
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Steroid and/or Prednisone Dependent Asthma
Conditions
Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis
Trial Timeline
Mar 1, 2014 → Sep 1, 2017
NCT ID
NCT02049294About Omalizumab (Xolair) + Placebo
Omalizumab (Xolair) + Placebo is a phase 2/3 stage product being developed by Novartis for Steroid and/or Prednisone Dependent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT02049294. Target conditions include Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis.
What happened to similar drugs?
4 of 6 similar drugs in Steroid and/or Prednisone Dependent Asthma were approved
Approved (4) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02049294 | Phase 2/3 | Completed |
| NCT01803763 | Phase 2/3 | Completed |
| NCT00851370 | Phase 2 | Withdrawn |
Competing Products
8 competing products in Steroid and/or Prednisone Dependent Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide Nasal | Johnson & Johnson | Approved | 47 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 43 |
| Ruxolitinib | Novartis | Approved | 50 |
| Ruxolitinib (RUX) + Best Available Therapy (BAT) | Novartis | Phase 3 | 40 |
| Rituximab | Roche | Phase 2 | 31 |
| Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab | Amgen | Phase 3 | 40 |
| Levetiracetam, Keppra | UCB | Approved | 43 |
| Itacitinib + Tocilizumab | Incyte | Phase 1 | 18 |